Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

We have previously described the safety and efficacy of pegylated interferon-α2a therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated myelofibrosis followed in centers affiliated to the French Intergroup of Myeloproliferative neoplasms. In this study, we report their long-t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Haematologica
Autori principali: Ianotto, Jean-Christophe, Chauveau, Aurélie, Boyer-Perrard, Françoise, Gyan, Emmanuel, Laribi, Kamel, Cony-Makhoul, Pascale, Demory, Jean-Loup, de Renzis, Benoit, Dosquet, Christine, Rey, Jerome, Roy, Lydia, Dupriez, Brigitte, Knoops, Laurent, Legros, Laurence, Malou, Mohamed, Hutin, Pascal, Ranta, Dana, Benbrahim, Omar, Ugo, Valérie, Lippert, Eric, Kiladjian, Jean-Jacques
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ferrata Storti Foundation 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5830374/
https://ncbi.nlm.nih.gov/pubmed/29217781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.181297
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi